{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:14:16Z","timestamp":1745554456540,"version":"3.40.4"},"reference-count":1,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[1997,12,12]],"date-time":"1997-12-12T00:00:00Z","timestamp":881884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1997,12,12]],"date-time":"1997-12-12T00:00:00Z","timestamp":881884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[1998]]},"abstract":"<jats:p>Twenty-three patients with advanced melanoma were treated with a combination of subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a (IFN-\u03b1) with chemotherapy consisting of four cycles of carboplatin (300 mg\/m&lt;sup&gt;2&lt;\/sup&gt;, day 1) and vinblastine (6 mg\/m&lt;sup&gt;2&lt;\/sup&gt;, day 1), every 28 days (CV-IL-IF). IL-2 was given at a dose of 4.5 \u00d7 10&lt;sup&gt;6&lt;\/sup&gt; U twice daily on days 3\u20136 and days 21\u201324 of each cycle; IFN-\u03b1 dose was 4.5 \u00d7 10&lt;sup&gt;6&lt;\/sup&gt; U, starting on day 2, thrice weekly. Immunotherapy was intended to continue for 6 months. Of the 23 analyzed patients, 4 (17%) achieved an objective response, including 1 complete and 3 partial responses, in nonvisceral metastatic disease. The median time to progression was 5 months and the median survival from onset of the treatment 6 months (range 1\u201314 months). Four patients discontinued the treatment, due to nonhaematologic toxicity; 3 for severe weakness and the 4th patient for long-lasting CNS side-effects. Other grade 3\u20134 toxicities included weight loss (22%), nausea and vomiting (17%) and alopecia (13%). The haematologic toxicity was acceptable. No toxic death was noted. It is con cluded that the CV-IL-IF regimen has limited activity and moderate toxicity.<\/jats:p>","DOI":"10.1159\/000011834","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T15:43:24Z","timestamp":1050421404000},"page":"48-52","source":"Crossref","is-referenced-by-count":3,"title":["Subcutaneous Low Doses of Interleukin-2 and Recombinant Interferon Alpha with Carboplatin and Vinblastine in Patients with Advanced Melanoma&lt;sup&gt;1&lt;\/sup&gt;"],"prefix":"10.1159","volume":"55","author":[{"given":"D.","family":"Bafaloukos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bakoyiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Karvounis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[1997,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199606000-00018"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/11834","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/11834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:53:10Z","timestamp":1745470390000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000011834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,12,12]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[1998,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000011834","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[1997,12,12]]}}}